๐๐ก๐ “๐๐ฎ๐ซ๐ฉ๐ฅ๐ ๐๐ช๐ฎ๐ข๐ซ๐ซ๐๐ฅ” ๐๐๐ฅ๐๐ง๐ญ ๐๐๐ฉ Recruiters often call this the โpurple squirrelโ profile: a “unicorn” blending deep regulatory strategy, therapeutic area such as neurology research expertise, with a fundamental understanding of AI application.
Archive for January 3rd, 2026
๐ ๐ซ๐จ๐ฆ ๐๐ฌ๐ฌ๐ข๐ฌ๐ญ๐๐ง๐๐ ๐ญ๐จ ๐๐ ๐๐ง๐๐ฒ: ๐๐ก๐ฒ ๐๐ซ๐๐๐ข๐ฌ๐ข๐จ๐ง ๐๐๐ซ๐ ๐๐ข๐๐ง๐ญ๐ฌ ๐๐๐๐ ๐๐จ๐ฆ๐๐ข๐ง๐๐ ๐๐๐ ๐ฎ๐ฅ๐๐ญ๐จ๐ซ๐ฒ/๐๐ก๐๐ซ๐๐ฉ๐๐ฎ๐ญ๐ข๐ ๐๐ซ๐๐/๐๐ ๐๐ค๐ข๐ฅ๐ฅ๐๐ ๐๐๐ฅ๐๐ง๐ญ
Posted by Michael A. S. Guth on January 3rd, 2026
Posted in 
Intriguing Comments on Depression
Posted by Michael A. S. Guth on January 3rd, 2026
From Thomas Tsangaras: โDepression is your body saying: โI donโt want to be this character anymore.โโ โI donโt want to be this character anymore.โ So many people quietly say that line. Not just in the context of mental health but in the context of work, identity, and environments. Sometimes what we call burnout or depression […]
Beyond the 16-Week Snapshot: Why Data Snapshots Mask the Reality of Chronic Therapy
Posted by Michael A. S. Guth on January 3rd, 2026
Beyond the 16-Week Snapshot: Why Data Snapshots Mask the Reality of Chronic Therapy In my independent review of the CARES-310 trial (Camrelizumab-Rivoceranib), I analyzed a common pitfall in modern drug development: the reliance on 16-week primary endpoints to justify long-term therapeutic narratives. While a 16-week data cut can deliver a clean p-value for a regulatory […]